Management of Heart Failure, Durable Left Ventricular Assist Device, and Heart Transplant Patients in the COVID-19 Era.
Nadia FidaPublished in: Methodist DeBakey cardiovascular journal (2021)
Our world is facing recurrent waves of coronavirus disease 2019 (COVID-19) with the emergence of more infectious strains of the novel coronavirus, SARS-CoV-2. Multiple studies have established that heart failure (HF) patients are at high risk of severe disease and poor outcomes with COVID-19. Management of COVID-19 in patients with HF, heart transplant, and those supported with durable left ventricular assist devices present an arduous challenge due to underlying complex health conditions and overlap of symptoms. Based on available data, this review outlines the management of this vulnerable patient population who either present with COVID-19 with preexisting HF or with de novo HF from COVID-19.
Keyphrases
- coronavirus disease
- sars cov
- heart failure
- respiratory syndrome coronavirus
- left ventricular
- end stage renal disease
- ejection fraction
- acute heart failure
- newly diagnosed
- peritoneal dialysis
- healthcare
- public health
- atrial fibrillation
- type diabetes
- escherichia coli
- mental health
- prognostic factors
- acute myocardial infarction
- coronary artery disease
- aortic stenosis
- cardiac resynchronization therapy
- physical activity
- patient reported outcomes
- electronic health record
- skeletal muscle
- hypertrophic cardiomyopathy
- deep learning
- health information
- depressive symptoms
- aortic valve
- percutaneous coronary intervention